Almac Discovery Enters Into Licensing Agreement for the Development & Commercialization of ALM301 

Almac Discovery, a member of the Almac Group, recently announced an out-licensing partnership with an undisclosed biotechnology company in order to advance the development and commercialization of one of its portfolio projects – ALM301.

ALM301 is a novel, patent-protected, potent, subtype selective Akt kinase inhibitor with good pharmacokinetic properties across multiple species, and an excellent selectivity profile. It has demonstrated robust efficacy in preclinical prostate, breast, and other cancer xenograft models, both as a single agent and in combination with standard chemotherapeutic agents, where synergy has been observed.

The molecule is currently in late-stage preclinical development, and the partner will complete this before progressing into the clinical development phase.

Dr. Stephen Barr, Managing Director & President, Almac Discovery, said “This new out-licensing agreement represents a further example of the business model we have pursued at Almac Discovery in action – namely the discovery of new, innovative drug candidates for development through external partnerships and collaborations.”

This announcement comes just 2 weeks after Almac Discovery disclosed a new strategic collaboration with MSD on selected Deubiquitinase (DUB) enzyme therapeutic targets for neurodegenerative disease. In addition, in March, the company also announced the clinical advancement by its partner Debiopharm (Switzerland), of Debio 0123, an oral, potent and highly selective WEE-1 inhibitor, in combination with carboplatin in patients with advanced solid tumors. The molecule was initially discovered and developed by Almac Discovery, before being out-licensed to Debiopharm in 2017.

Almac Discovery has grown from strength to strength with four significant agreements signed in the past 5 years. It continues to build its internal pipeline through partnerships and collaborations to drive forward a dedicated effort towards the development of novel therapeutics for the treatment of disease, and to make a real and lasting contribution towards the advancement of human health.

Almac Discovery is an innovative research driven biotech company dedicated to the discovery and development of First-in-Class therapeutics across a range of therapeutic areas including neuroscience, muscle-wasting, oncology, and inflammation. Almac Discovery focuses on the discovery to preclinical stage, seeking to licence programs early with a pharmaceutical partner for further development. For more information, please visit www.almacgroup.com/discovery or e-mail alan.lamont@almacgroup.com.

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture. The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia. To keep up to date with latest news, follow Almac Group on Twitter and LinkedIn or visit almacgroup.com.